Recent Updates
Recently added Catalysts
REGN Positive Sentiment

Regeneron Announces Investor Conference Presentations

Key Takeaway: Regeneron Pharmaceuticals will participate in three upcoming investor conferences. The events include the Jefferies Global Healthcare Conference on November 17, the Evercore Healthcare Conference on December 1, and Citi's Global Healthcare Conference on December 2. Webcasts will be available on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Regeneron schedules three investor conference presentations.
  • Company provides webcast access for shareholder engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+54%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
Cenvacibart
Phase 3 · Secondary Stroke

Full Press Release Details

TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
• 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m. GMT (9:00 a.m. ET) on Tuesday, November 17, 2026
• 9th Annual Evercore Healthcare Conference at 1:45 p.m. ET on Tuesday, December 1, 2026
• Citi’s 2026 Global Healthcare Conference at 9:40 a.m. ET on Wednesday, December 2, 2026
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.
About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Contact Information: Investor Relations Ryan Crowe 914.847.8790 ryan.crowe@regeneron.com

Frequently Asked Questions

When is Regeneron's next investor conference?

Regeneron's next conference is on November 17, 2026.

How can I access the conference webcasts?

Webcasts can be accessed from Regeneron's Investors & Media page.

What is the focus of Regeneron's presentations?

Regeneron will discuss its innovative drug development and pipeline.

How long will the webcasts be available?

Replays and transcripts will be archived for at least 30 days.

Last updated: Nov 2, 2026